Italy Asthma COPD Drugs Market

ID: MRFR/Pharma/47722-HCR
200 Pages
Satyendra Maurya
Last Updated: April 06, 2026
Italy Asthma COPD Drugs Market Research Report: Size, Share, Trend Analysis By Drug Class (Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers), By Route of Administration (Inhalation, Oral, Injection, Nasal), By Applications (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension) and By Patient Group (Adult, Pediatric, Geriatric) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Drug Class (USD Million)
      1. 4.1.1 Bronchodilators
      2. 4.1.2 Corticosteroids
      3. 4.1.3 Combination Drugs
      4. 4.1.4 Leukotriene Modifiers
    2. 4.2 Pharmaceutical, BY Route of Administration (USD Million)
      1. 4.2.1 Inhalation
      2. 4.2.2 Oral
      3. 4.2.3 Injection
      4. 4.2.4 Nasal
    3. 4.3 Pharmaceutical, BY Application (USD Million)
      1. 4.3.1 Asthma
      2. 4.3.2 Chronic Obstructive Pulmonary Disease
      3. 4.3.3 Allergic Rhinitis
      4. 4.3.4 Pulmonary Hypertension
    4. 4.4 Pharmaceutical, BY Patient Group (USD Million)
      1. 4.4.1 Adult
      2. 4.4.2 Pediatric
      3. 4.4.3 Geriatric
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 GlaxoSmithKline (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Boehringer Ingelheim (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 AstraZeneca (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Teva Pharmaceutical Industries (IL)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Merck & Co. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Roche (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Mylan (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 ITALY MARKET ANALYSIS BY DRUG CLASS
    3. 6.3 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    4. 6.4 ITALY MARKET ANALYSIS BY APPLICATION
    5. 6.5 ITALY MARKET ANALYSIS BY PATIENT GROUP
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY DRUG CLASS, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY DRUG CLASS, 2024 TO 2035 (USD Million)
    14. 6.14 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    16. 6.16 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
    18. 6.18 PHARMACEUTICAL, BY PATIENT GROUP, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY PATIENT GROUP, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
      2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
      3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
      4. 7.2.4 BY PATIENT GROUP, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Italy Italy Asthma COPD Drugs Market Segmentation

Italy Asthma COPD Drugs Market By Drug Class (USD Million, 2025-2035)

  • Bronchodilators
  • Corticosteroids
  • Combination Drugs
  • Leukotriene Modifiers

Italy Asthma COPD Drugs Market By Route of Administration (USD Million, 2025-2035)

  • Inhalation
  • Oral
  • Injection
  • Nasal

Italy Asthma COPD Drugs Market By Application (USD Million, 2025-2035)

  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Allergic Rhinitis
  • Pulmonary Hypertension

Italy Asthma COPD Drugs Market By Patient Group (USD Million, 2025-2035)

  • Adult
  • Pediatric
  • Geriatric

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035